Search
Displaying 661–670 of 762 for “retinitis clinical trial”
-
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
In the PressIndustry Veteran Brings Broad Ophthalmology Research & Development Expertise.
-
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
Research NewsThis new treatment can reduce the frequency of injections into the eye
-
Foundation News
Commitment to expand translational research acceleration program and fund career development award.
-
In Memoriam: Dr. Alan Laties – Early Leader in Retinal Research
Beacon StoriesAlan M. Laties, MD, passed away on Sunday, December 26 at the age of 90.
-
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
Research NewsFirst two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12
-
Telling His Story of Resilience
Beacon StoriesChad has been working in the corporate world for the last 20 years. But after becoming the first blind executive to graduate from the Harvard Business School leadership program, he realized his purpose in life is to help others by sharing the lessons he learned while losing his eyesight. He can now add published author to his repertoire with his new book, Blind Ambition.
-
Foundation Fighting Blindness to Host National Virtual VisionWalk
Foundation NewsThe Spring Virtual VisionWalk on June 12th will raise awareness and fund research finding treatments and cures for blinding retinal diseases.
-
The bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including retinal and eye diseases.
-
Ambitious Swimmer Spreading Optimism
Beacon Stories26-year-old Becca is a two-time Paralympic swimmer for Team USA, diagnosed with Usher syndrome type 1 (USH1) at only four years old. But she has never let her diagnosis with Usher syndrome stop her from doing exactly what she puts her mind to.
-
Beacon Stories
American Banker dubbed her as “the sharpest mind analyzing banking policy today – maybe ever.”
